Patient & Population Decisions
Define the right patients before your trial starts. Increase the POS of your clinical trial.
Drugs are not equally effective across all patients. K Pro’s specialized AI skills work together to understand treatment response and identify biomarkers that define the patients most likely to benefit.
%20(1).jpg)
Solving actual pharma R&D challenges in minutes
Getting answers
I’m designing the inclusion and exclusion criteria for my upcoming Phase II NSCLC trial. I need deeper insights to define the right patient subgroups and associated biomarkers.
Clinical Development Lead, Oncology
ehpDefine the right patient population in minutes
Understand the co-mutation landscape of your target indication, the immune biology of key subgroups, and the biomarkers to refine your inclusion and exclusion criteria. Gain confidence to design your clinical trial and advance your asset based on real-world multimodal data.
Understand the co-mutation landscape of your target indication, the immune biology of key subgroups, and the biomarkers to refine your inclusion and exclusion criteria. Gain confidence to design your clinical trial and advance your asset based on real-world multimodal data.
Use K Pro to:
Navigate biological features across multimodal data.
Define optimal populations maximizing likelihood of drug response.
Identify responder signatures and successful therapy patterns.
Converse with histological data to understand the tumor microenvironment, characterize patient populations, and derive actionable biomarkers.
Ready to get started?
Discover how K Pro can transform your drug discovery and development. Connect with our team to explore how we can support your specific needs.
